Every material Form 8-K BIOVIE INC. has filed with the SEC since November 13, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BioVie Inc. agreed on November 3, 2026 to sell shares and pre-funded warrants in a registered direct offering and common warrants in a concurrent private placement, with aggregate gross proceeds of approximately $4.74 million before fees and expenses. The offering closed on November 5, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes. The deal adds shares and dilutive warrants, and the company has agreed to restrictions on new share issuances.
Registered direct offering: 960,000 shares at $1.60 per share plus 2,002,500 pre-funded warrants at $1.5999 each
Concurrent private placement: 2,962,500 common warrants exercisable at $1.70 per share, starting six months after issuance
Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
Company and directors and officers agreed to issuance and sale restrictions for 60 days after the November 5, 2026 closing
BioVie entered a sales agreement with A.G.P./Alliance Global Partners allowing it to sell up to $6,464,341 of Class A common stock through the agent over time. The company pays the agent a 3.0% commission on gross proceeds and says it may use proceeds for general corporate purposes; it has no obligation to sell any shares. Shareholders may face dilution if the shares are sold.
Aggregate offering price of up to $6,464,341 in Placement Shares under the Sales Agreement dated September 11, 2026
Agent commission of 3.0% of gross proceeds, plus reimbursement of certain specified expenses
Sales made under Form S-3 (File No. 333-296924), declared effective June 29, 2026; offering ends no later than the registration statement's third anniversary
Company has no obligation to sell shares and may suspend or terminate the offering at any time
BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in 57 patients with early-stage Parkinson's disease, with statistically significant improvements versus placebo on several measures. The results are exploratory, the study was small, and the company disclosed no revenue, earnings, or financing figures, so the filing gives shareholders clinical data rather than financial results.
Trial of 57 patients randomized 1:1 to 20 mg bezisterim or placebo twice daily for 12 weeks
Composite EPNIC-15 endpoint: bezisterim -0.04 vs. placebo +0.18 (p=0.0006), per the company
Reported adverse event incidence of 39.3% with bezisterim vs. 51.7% with placebo; no severe or serious adverse events
Conference call set for 4:15 p.m. EDT on August 12, 2026
At its November 10, 2025 annual meeting, BioVie's stockholders approved an amended and restated 2019 Omnibus Equity Incentive Plan, effective that day. The amendment raises the number of common shares authorized for issuance under the plan to 3,100,000, allowing the company to keep granting equity compensation to employees, directors and consultants.
Stockholders approved the amended and restated 2019 Omnibus Equity Incentive Plan on November 10, 2025, effective the same day.
Authorized shares under the plan increased to 3,100,000 common shares.
Full plan terms are in Appendix A to the Definitive Proxy Statement on Schedule 14A filed September 25, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BIOVIE INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →